Pharma Q3 Results Preview: Merck & Co., Merck KGaA

 
• By Emily Hayes, Mandy Jackson, Lucie Ellis-Taitt, and Kevin Grogan

Investors will be eager to hear updates on Merck & Co.'s Keytruda market share versus other PD-1/L1 competitors in lung cancer, as well as other indications; Merck KGaA followers are watching for what sort of start its Pfizer Inc.-partnered checkpoint inhibitor Bavencio and the new multiple sclerosis drug Mavenclad have got off to.

More from Earnings

More from Business